SenoRx Announces Court Has Set Schedule for Summary Judgment Briefing and Trial in...

SenoRx Announces Court Has Set Schedule for Summary Judgment Briefing and Trial
in Its Lawsuit With Hologic

IRVINE, Calif., May 11, 2009 (GLOBE NEWSWIRE) -- SenoRx, Inc. (Nasdaq:SENO)
today announced that the United States District Court for the Northern District
of California has issued a schedule for a summary judgment briefing and trial
date in response to a joint stipulation, which was filed by both SenoRx and
Hologic on April 14, 2009 in their pending matter before the Court. The joint
stipulation requested that the Court allow summary judgment briefing and
argument as to certain patent validity and infringement issues.

The schedule set by the Court is set forth below.

For summary judgment:

Opening briefs: May 20, 2009
Opposition briefs: June 19, 2009
Reply briefs: July 10, 2009
Argument: August 21, 2009
Trial Start Date: October 13

Based on the above court schedule, SenoRx reaffirms its estimate that patent
litigation expense in the second quarter of 2009 remains unchanged from a range
between $450,000 and $600,000. SenoRx will provide additional guidance on
litigation expense when results for the second quarter of 2009 are reported.

About SenoRx

SenoRx (Nasdaq:SENO) develops, manufactures and sells minimally invasive medical
devices used by breast care specialists for the diagnosis and treatment of
breast cancer, including its EnCor(r) vacuum-assisted breast biopsy system and
Contura(tm) MLB catheter for delivering radiation to the tissue surrounding the
lumpectomy cavity following surgery for breast cancer. SenoRx's field sales
organization serves over 1,000 breast diagnostic and treatment centers in the
United States and Canada. In addition, SenoRx sells several of its products
through distribution partners in more than 30 countries outside the U.S. and
Canada. The company's line of breast care products includes biopsy disposables,
biopsy capital equipment, diagnostic adjunct products and therapeutic
disposables. SenoRx is developing additional minimally invasive products for the
diagnosis and treatment of breast cancer. For more information, visit the
company's website at www.senorx.com.

The SenoRx, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=3605

-0-
CONTACT: SenoRx, Inc.
Lila Churney, Director of Investor Relations
949.362.4800 ext.132